Nasdaq · CIK 0001372514
KPRX KIORA PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 25 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Signals
Open-market buys and sells at KIORA PHARMACEUTICALS INC, scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Keith J. Lane other | AGrant or award Stock Option (right to buy)derivative | +55,000 | $0.00 | $0 | 55,000 | 25 d ago |
| Apr 1, 2025 | Eric Joseph Daniels Chief Development Officer | AGrant or award Common Stock | +7,772 | $0.00 | $0 | 26,375 | Apr 2, 2025 |
| Apr 1, 2025 | David Hollander director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Apr 1, 2025 | Lisa Walters-Hoffert director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Apr 1, 2025 | Carmine N. Stengone director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Apr 1, 2025 | Praveen Tyle director | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Apr 2, 2025 |
| Apr 1, 2025 | Erin Parsons director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Apr 1, 2025 | Aron Shapiro director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Apr 2, 2025 |
| Apr 1, 2025 | Brian M. Strem President and CEO | AGrant or award Common Stock | +15,941 | $0.00 | $0 | 46,103 | Apr 2, 2025 |
| Apr 1, 2025 | Melissa Tosca CFO | AGrant or award Common Stock | +7,772 | $0.00 | $0 | 21,371 | Apr 2, 2025 |
| Apr 1, 2025 | Eric Joseph Daniels Chief Development Officer | AGrant or award Stock Option (right to buy)derivative | +15,543 | $0.00 | $0 | 15,543 | Apr 2, 2025 |
| Apr 1, 2025 | Brian M. Strem President and CEO | AGrant or award Stock Option (right to buy)derivative | +31,883 | $0.00 | $0 | 31,883 | Apr 2, 2025 |
| Apr 1, 2025 | Melissa Tosca CFO | AGrant or award Stock Option (right to buy)derivative | +15,543 | $0.00 | $0 | 15,543 | Apr 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Eric Joseph DanielsChief Development Officer
- David Hollanderofficer, director
- Keith J. Laneother
- Erin Parsonsdirector
- Aron Shapirodirector
- Carmine N. Stengoneceo, president, officer, director
- Brian M. StremPresident and CEO
- Praveen Tyledirector
- Melissa ToscaCFO
- Lisa Walters-Hoffertdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.